Principal Financial Group Inc. raised its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 0.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 83,338 shares of the biopharmaceutical company’s stock after buying an additional 610 shares during the period. Principal Financial Group Inc. owned about 0.31% of Bellicum Pharmaceuticals worth $1,029,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of BLCM. Eagle Ridge Investment Management acquired a new position in Bellicum Pharmaceuticals during the first quarter valued at about $144,000. American International Group Inc. boosted its stake in shares of Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 852 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Bellicum Pharmaceuticals during the first quarter valued at $171,000. Trexquant Investment LP purchased a new stake in shares of Bellicum Pharmaceuticals during the first quarter valued at $211,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Bellicum Pharmaceuticals during the first quarter valued at $277,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) opened at 7.96 on Friday. Bellicum Pharmaceuticals, Inc. has a 12-month low of $7.59 and a 12-month high of $23.11. The firm has a 50-day moving average price of $11.38 and a 200 day moving average price of $12.32. The company’s market capitalization is $264.48 million.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period in the previous year, the company earned ($0.61) earnings per share. On average, equities research analysts predict that Bellicum Pharmaceuticals, Inc. will post ($2.95) earnings per share for the current year.
BLCM has been the topic of several recent research reports. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $31.00 price target on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Raymond James Financial, Inc. reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 price target on shares of Bellicum Pharmaceuticals in a research note on Monday, June 26th. BidaskClub cut Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Finally, Jefferies Group LLC reduced their price target on Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, May 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $26.20.
In related news, VP Ken Moseley sold 13,823 shares of the business’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $12.26, for a total transaction of $169,469.98. Following the transaction, the vice president now directly owns 14,314 shares in the company, valued at approximately $175,489.64. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Alan A. Musso sold 6,311 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $12.24, for a total value of $77,246.64. The disclosure for this sale can be found here. Insiders sold a total of 30,571 shares of company stock worth $367,295 over the last quarter. Company insiders own 23.30% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.